Business
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In preclinical studies, APVO711 demonstrates dual anti-cancer ...
About this update from Aptevo Therapeutics Inc.
[{"type":"text","content":"As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform","length":194,"tagName":"p"},{"type":"text","content":"In preclinical studies, APVO711 demonstrates dual anti-cancer functionality with broad solid tumor potential and developability","length":127,"tagName":"p"},{"type":"text","content":"SEATTLE, WASHINGTON / ACCESS Newswire / May 8, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today provided a program update for APVO711, a dual mechanism bispecific utilizing the PD-L1 arm to block the PD-1/PD-L1 pathway and the CD40 arm to enhance T cell priming through activation of the stimulatory receptor CD40 on antigen presenting cells. This update highlights the depth and scientific versatility of Aptevo's existing pipeline and reinforces the Company's ability to advance differentiated candidates for solid tumors with significant unmet need. Currently in preclinical development, APVO711 reflects the potential of Aptevo's platform-based strategy to generate bispecific therapeutics with novel mechanisms and broad clinical relevance.","length":932,"tagName":"p"},{"type":"text","content":""With APVO711, we're advancing an innovative dual-mechanism approach to immunotherapy-one that not only boosts the immune system through PD-L1 blockade but also facilitates T-cell priming via CD40 activation. This is important in the development of new therapeutics for cancers that have proven resistant to standard checkpoint therapies. We believe APVO711 has the potential to unlock deeper, more sustained responses, and ultimately expand the reach of immunotherapy to patients who need it most," said Marvin White, President and CEO of Aptevo.","length":561,"tagName":"p"},{"type":"text","content":"About APVO711","length":13,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Novel Mechanism: APVO711 is a bispecific antibody targeting PD-L1 × CD40-combining checkpoint inhibition with immune activation in a single molecule.","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"Designed for Pote...